JP2020517663A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517663A5 JP2020517663A5 JP2019557486A JP2019557486A JP2020517663A5 JP 2020517663 A5 JP2020517663 A5 JP 2020517663A5 JP 2019557486 A JP2019557486 A JP 2019557486A JP 2019557486 A JP2019557486 A JP 2019557486A JP 2020517663 A5 JP2020517663 A5 JP 2020517663A5
- Authority
- JP
- Japan
- Prior art keywords
- tyrosine
- methyl
- amino
- propanoate
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 23
- 229940122110 Tyrosine hydroxylase inhibitor Drugs 0.000 claims description 16
- 208000002780 macular degeneration Diseases 0.000 claims description 14
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 9
- VXYFARNRGZWHTJ-SBSPUUFOSA-N hydron;methyl (2r)-2-amino-3-(4-hydroxyphenyl)propanoate;chloride Chemical compound Cl.COC(=O)[C@H](N)CC1=CC=C(O)C=C1 VXYFARNRGZWHTJ-SBSPUUFOSA-N 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- NHTGHBARYWONDQ-SNVBAGLBSA-N (2r)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid Chemical compound OC(=O)[C@@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-SNVBAGLBSA-N 0.000 claims description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 6
- 208000017442 Retinal disease Diseases 0.000 claims description 6
- 206010038923 Retinopathy Diseases 0.000 claims description 6
- -1 ester hydrochloride Chemical class 0.000 claims description 6
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 claims description 5
- NHTGHBARYWONDQ-UHFFFAOYSA-N (+-)-α-methyl-tyrosine Chemical compound OC(=O)C(N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-UHFFFAOYSA-N 0.000 claims description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 4
- NYPYHUZRZVSYKL-UHFFFAOYSA-N -3,5-Diiodotyrosine Natural products OC(=O)C(N)CC1=CC(I)=C(O)C(I)=C1 NYPYHUZRZVSYKL-UHFFFAOYSA-N 0.000 claims description 4
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000005642 Oleic acid Substances 0.000 claims description 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical group CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 claims description 4
- 210000000664 rectum Anatomy 0.000 claims description 4
- 229940082991 antihypertensives tyrosine hydroxylase inhibitors Drugs 0.000 claims description 3
- 229960004441 tyrosine Drugs 0.000 claims description 3
- SWZCTMTWRHEBIN-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C=C1 SWZCTMTWRHEBIN-QFIPXVFZSA-N 0.000 claims description 2
- CNBUSIJNWNXLQQ-NSHDSACASA-N (2s)-3-(4-hydroxyphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNBUSIJNWNXLQQ-NSHDSACASA-N 0.000 claims description 2
- JZKXXXDKRQWDET-UHFFFAOYSA-N 2-azaniumyl-3-(3-hydroxyphenyl)propanoate Chemical compound OC(=O)C(N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-UHFFFAOYSA-N 0.000 claims description 2
- WRFPVMFCRNYQNR-UHFFFAOYSA-N 2-hydroxyphenylalanine Chemical compound OC(=O)C(N)CC1=CC=CC=C1O WRFPVMFCRNYQNR-UHFFFAOYSA-N 0.000 claims description 2
- WWYDYZMNFQIYPT-UHFFFAOYSA-L 2-phenylpropanedioate Chemical compound [O-]C(=O)C(C([O-])=O)C1=CC=CC=C1 WWYDYZMNFQIYPT-UHFFFAOYSA-L 0.000 claims description 2
- ACWBBAGYTKWBCD-ZETCQYMHSA-N 3-chloro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(Cl)=C1 ACWBBAGYTKWBCD-ZETCQYMHSA-N 0.000 claims description 2
- FBTSQILOGYXGMD-LURJTMIESA-N 3-nitro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 FBTSQILOGYXGMD-LURJTMIESA-N 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical group N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 2
- 229960000623 carbamazepine Drugs 0.000 claims description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- GITKQXFBNJTMRP-QRPNPIFTSA-N ethyl (2s)-2-amino-3-(4-hydroxy-3-nitrophenyl)propanoate;hydrochloride Chemical compound Cl.CCOC(=O)[C@@H](N)CC1=CC=C(O)C([N+]([O-])=O)=C1 GITKQXFBNJTMRP-QRPNPIFTSA-N 0.000 claims description 2
- BQULAXAVRFIAHN-UHFFFAOYSA-N ethyl 2-amino-3-(4-hydroxyphenyl)propanoate;hydron;chloride Chemical compound Cl.CCOC(=O)C(N)CC1=CC=C(O)C=C1 BQULAXAVRFIAHN-UHFFFAOYSA-N 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- BPKBTKQFMPZVNO-SSDOTTSWSA-N methyl (2r)-2-amino-3-(2,6-dichloro-3-hydroxy-4-methoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=C(Cl)C=C(OC)C(O)=C1Cl BPKBTKQFMPZVNO-SSDOTTSWSA-N 0.000 claims description 2
- ATVDFEWFLSSKBM-MRVPVSSYSA-N methyl (2r)-2-amino-3-(2-chloro-3,4-dimethoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC=C(OC)C(OC)=C1Cl ATVDFEWFLSSKBM-MRVPVSSYSA-N 0.000 claims description 2
- WOOVWLVXVNIALE-SSDOTTSWSA-N methyl (2r)-2-amino-3-(2-chloro-3-hydroxy-4-methoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC=C(OC)C(O)=C1Cl WOOVWLVXVNIALE-SSDOTTSWSA-N 0.000 claims description 2
- JRBGZVHYLIYGFT-SECBINFHSA-N methyl (2r)-2-amino-3-(3-chloro-4,5-dimethoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC(Cl)=C(OC)C(OC)=C1 JRBGZVHYLIYGFT-SECBINFHSA-N 0.000 claims description 2
- KWTIOVPQMRSIJF-MRVPVSSYSA-N methyl (2r)-2-amino-3-(3-chloro-4-hydroxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC=C(O)C(Cl)=C1 KWTIOVPQMRSIJF-MRVPVSSYSA-N 0.000 claims description 2
- QUBSTZJVDZUTFR-SECBINFHSA-N methyl (2r)-2-amino-3-(3-chloro-4-methoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC=C(OC)C(Cl)=C1 QUBSTZJVDZUTFR-SECBINFHSA-N 0.000 claims description 2
- ZSDSFDQBWLLWEN-MRVPVSSYSA-N methyl (2r)-2-amino-3-(3-chloro-5-fluoro-4-hydroxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC(F)=C(O)C(Cl)=C1 ZSDSFDQBWLLWEN-MRVPVSSYSA-N 0.000 claims description 2
- MWZPENIJLUWBSY-SECBINFHSA-N methyl (2r)-2-amino-3-(4-hydroxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC=C(O)C=C1 MWZPENIJLUWBSY-SECBINFHSA-N 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- 229960000604 valproic acid Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- URTGFUAPYILQFF-SECBINFHSA-N methyl (2r)-2-amino-3-(2-chloro-4-hydroxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=CC=C(O)C=C1Cl URTGFUAPYILQFF-SECBINFHSA-N 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 3
- 238000012014 optical coherence tomography Methods 0.000 description 3
- 230000004233 retinal vasculature Effects 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- BICWDWHXTTXTDU-MRVPVSSYSA-N methyl (2r)-2-amino-3-(2,6-dichloro-3,4-dimethoxyphenyl)propanoate Chemical compound COC(=O)[C@H](N)CC1=C(Cl)C=C(OC)C(OC)=C1Cl BICWDWHXTTXTDU-MRVPVSSYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488161P | 2017-04-21 | 2017-04-21 | |
| US62/488,161 | 2017-04-21 | ||
| PCT/US2018/028552 WO2018195411A1 (en) | 2017-04-21 | 2018-04-20 | Compositions and methods for treating retinopathy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517663A JP2020517663A (ja) | 2020-06-18 |
| JP2020517663A5 true JP2020517663A5 (cg-RX-API-DMAC7.html) | 2021-05-06 |
| JP7171611B2 JP7171611B2 (ja) | 2022-11-15 |
Family
ID=62117055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019557486A Active JP7171611B2 (ja) | 2017-04-21 | 2018-04-20 | 網膜症を治療するための組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11351136B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3612225A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7171611B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190138683A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110769855A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018254556B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3060417A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA201992515A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019012476A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12019502380A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018195411A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020232227A1 (en) | 2019-05-14 | 2020-11-19 | Tyme, Inc. | Compositions and methods for treating cancer |
| US10905698B1 (en) | 2020-05-14 | 2021-02-02 | Tyme, Inc. | Methods of treating SARS-COV-2 infections |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0451422A1 (en) * | 1990-04-13 | 1991-10-16 | Merrell Dow Pharmaceuticals Inc. | Pharmaceutically active fluoromethyltyrosine compounds |
| AU779908B2 (en) * | 1999-09-10 | 2005-02-17 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US7081482B2 (en) * | 1999-11-30 | 2006-07-25 | Alcon, Inc. | Use of β-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina |
| WO2002043763A2 (en) * | 2000-11-30 | 2002-06-06 | Pfizer Products Inc. | Combination of gaba agonists and aldose reductase inhibitors |
| NZ552816A (en) * | 2007-01-24 | 2009-05-31 | Bomac Research Ltd | Formulation for transdermal administration of antihyperthyroid drug comprising a penetration enhancer selected from oleic acid, d-limonene, pyrrolidones, a C2-C8 alcohol, glycol ethers, triacetin and combinations thereof |
| ES2400004T3 (es) * | 2007-01-29 | 2013-04-04 | Vlife Sciences Technologies Pvt Ltd. | Composición farmacéutica para el tratamiento de las complicaciones diabéticas |
| RU2470642C2 (ru) * | 2008-01-03 | 2012-12-27 | Байомарин Фармасьютикл Инк. | Аналоги птерина для лечения состояния, чувствительного к вн4 |
| US20100204325A1 (en) * | 2009-02-11 | 2010-08-12 | Allergan, Inc. | Valproic acid drug delivery systems and intraocular therapeutic uses thereof |
| PH12014501639B1 (en) * | 2012-01-17 | 2023-02-22 | Tyme Inc | Pharmaceutical compositions and methods |
| US9962362B2 (en) * | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| US20150111878A1 (en) * | 2013-10-22 | 2015-04-23 | Steven Hoffman | Compositions and methods for treating intestinal hyperpermeability |
| US9585841B2 (en) * | 2013-10-22 | 2017-03-07 | Tyme, Inc. | Tyrosine derivatives and compositions comprising them |
| AU2015371253B2 (en) * | 2014-12-23 | 2020-07-23 | Steven Hoffman | Transdermal formulations |
| US9687528B2 (en) | 2014-12-23 | 2017-06-27 | Steven Hoffman | Transdermal formulations |
-
2018
- 2018-04-20 CN CN201880034705.1A patent/CN110769855A/zh active Pending
- 2018-04-20 EA EA201992515A patent/EA201992515A1/ru unknown
- 2018-04-20 KR KR1020197033914A patent/KR20190138683A/ko not_active Withdrawn
- 2018-04-20 WO PCT/US2018/028552 patent/WO2018195411A1/en not_active Ceased
- 2018-04-20 AU AU2018254556A patent/AU2018254556B2/en active Active
- 2018-04-20 JP JP2019557486A patent/JP7171611B2/ja active Active
- 2018-04-20 US US15/958,598 patent/US11351136B2/en active Active
- 2018-04-20 MX MX2019012476A patent/MX2019012476A/es unknown
- 2018-04-20 EP EP18723209.5A patent/EP3612225A1/en active Pending
- 2018-04-20 CA CA3060417A patent/CA3060417A1/en not_active Abandoned
-
2019
- 2019-10-21 PH PH12019502380A patent/PH12019502380A1/en unknown
-
2022
- 2022-06-02 US US17/830,458 patent/US12364676B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2671208C2 (ru) | Композиции, содержащие 15-он эпк, и способы их применения | |
| JP2021001194A (ja) | 腸透過性亢進を治療するための組成物及び方法 | |
| US20200046669A1 (en) | Treatment of pulmonary arterial hypertension using therapeutically effective oral doses of 10-nitro-9(e)-octadec-9-enoic acid | |
| EP2982373B1 (en) | Methods and compostions for reducing body fat | |
| JP2023179467A (ja) | 投与および処置の方法 | |
| EP3668500A1 (en) | Methods of treatment of osteoarthritis with transdermal cannabidiol gel | |
| KR102000332B1 (ko) | 간내 담즙정체성 질환의 치료 | |
| EA030314B1 (ru) | Составы для уменьшения содержания жира | |
| JP6858131B2 (ja) | 自閉症を治療するための組成物及び方法 | |
| JPWO2013031729A1 (ja) | 糖尿病性心血管合併症の予防・治療剤 | |
| RU2204388C2 (ru) | ИБУПРОФЕНОВЫЙ ТИОЭФИР В КАЧЕСТВЕ ИНГИБИТОРА, ЗАВИСЯЩЕГО ОТ Nf-kB ОБРАЗОВАНИЯ МЕДИАТОРОВ ВОСПАЛЕНИЯ И БОЛИ | |
| JP2020517663A5 (cg-RX-API-DMAC7.html) | ||
| Scheman | Nodulocystic acne and hidradenitis suppurativa treated with acitretin: a case report | |
| BR112020000989A2 (pt) | métodos e composições para tratamento de dor com o uso de capsaicina | |
| JP2019516709A5 (cg-RX-API-DMAC7.html) | ||
| US12364676B2 (en) | Compositions and methods for treating retinopathy | |
| ES2250749T3 (es) | Uso de una composicion combinada que comprende propionil l-carnitina y otros farmacos para el tratamiento de la disfuncion erectil. | |
| Smirnov et al. | FRI0412 Spinal and sacroiliac joints inflammation in patients with radiographic axial spondyloarthritis treated with netakimab–16-weeks results of multicenter, randomized, double-blind, placebo-controlled phase III ASTERA study | |
| CA3207194A1 (en) | Fospropofol methods and compositions | |
| CN106983738B (zh) | 甲状腺激素及其药学上可接受的盐或前药在制备治疗和/或预防皮肤疾病的药物中的应用 | |
| JP7442263B2 (ja) | 白血球の接着を阻害する医薬の調製におけるトリアセチル－３－ヒドロキシフェニルアデノシンの使用 | |
| RU2704109C2 (ru) | Комбинация ретиноида и диола и эфира полиненасыщенной жирной кислоты | |
| JP2011032262A (ja) | Ｎｓａｉｄの長期使用のための医薬組成物 | |
| Juhasz | Necrobiosis lipoidica | |
| WO2025137024A1 (en) | Methods of treating cardiovascular disease associated with calcification |